Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

Information on the impact of bone metastasis and skeletal-related events (SREs) on mortality among prostate cancer patients is limited. Using the linked Surveillance, Epidemiology and End Results (SEER)-Medicare database, we identified men aged 65 years or older diagnosed with prostate cancer between July 1 1999 and December 31 2005 and followed to determine deaths through December 31 2006. We classified subjects as having bone metastasis and SREs as indicated by Medicare claims. Using Cox regression, we estimated mortality hazards ratios (HR) among men with bone metastasis with or without SRE, compared with men without bone metastasis. Among 126 978 men with prostate cancer (median follow-up, 3.3 years), 9746 (7.7%) had bone metastasis at prostate cancer diagnosis (1.7%) or during follow-up (5.9%). SREs occurred in 4296 (44%) men with bone metastasis. HRs for risk of death were 6.6 (95% CI=6.4–6.9) and 10.2 (95% CI=9.8–10.7), respectively, for men with bone metastasis but no SRE and for men with bone metastasis plus SRE, compared with men without bone metastasis. Bone metastasis was associated with mortality among prostate cancer patients. This association appeared to be stronger for bone metastasis plus SRE than for bone metastasis without SRE.

[1]  D. Shoskes,et al.  The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. , 1989, The Journal of urology.

[2]  F. Fazio,et al.  Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. , 2006, Urology.

[3]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[4]  D. Dodwell.  Malignant bone resorption: cellular and biochemical mechanisms. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[6]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[7]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[8]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[9]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[10]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[11]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[12]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[13]  M. Resnick,et al.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.

[14]  G. La Torre,et al.  Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. , 2008, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[15]  G. Andriole,et al.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma , 2000, Cancer.

[16]  A. Yokomizo,et al.  Skeletal‐related events in urological cancer patients with bone metastasis: A multicenter study in Japan , 2010, International journal of urology : official journal of the Japanese Urological Association.

[17]  P. Carroll,et al.  Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation , 2007, Cancer.

[18]  R. DiPaola,et al.  State-of-the-art treatment of metastatic hormone-refractory prostate cancer. , 2002, The oncologist.

[19]  D. Trump,et al.  Spinal cord compression in prostate cancer , 2005, Journal of Neuro-Oncology.

[20]  Fred Saad,et al.  Bone Metastases in Advanced Prostate Cancer , 2005 .

[21]  L. Lome,et al.  Neurological manifestation of metastatic prostatic carcinoma. , 1974, The Journal of urology.

[22]  R. Merrill.  Partitioned prostate cancer prevalence estimates: an informative measure of the disease burden , 2001, Journal of epidemiology and community health.

[23]  M. Resnick,et al.  Spinal cord compression secondary to prostate carcinoma: treatment and prognosis. , 1993, Journal of Urology.

[24]  H. Villavicencio.  Quality of life of patients with advanced and metastatic prostatic carcinoma. , 1993, European urology.

[25]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[26]  S. Cole,et al.  Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.

[27]  M. Cooperberg,et al.  Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. , 2009, Journal of the National Cancer Institute.

[28]  M. Zelefsky,et al.  Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy , 1992, Cancer.

[29]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[30]  M. H. Davis,et al.  Thirty Years of Medicare: Impact on the Covered Population , 1996, Health care financing review.

[31]  R. Tiguert,et al.  Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. , 2002, The Journal of urology.

[32]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  L. Kessler,et al.  Potential for Cancer Related Health Services Research Using a Linked Medicare‐Tumor Registry Database , 1993, Medical care.

[34]  K. Pienta,et al.  Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.

[35]  N. Clarke,et al.  Molecular mechanisms of metastasis in prostate cancer. , 2009, Asian journal of andrology.

[36]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[37]  H. Nishiyama,et al.  Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. , 2009, Urology.

[38]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[39]  J. Droz,et al.  Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. , 2003, Clinical prostate cancer.

[40]  D. Kuban,et al.  Characteristics of spinal cord compression in adenocarcinoma of prostate. , 1986, Urology.